Table 1 Baseline characteristics according to acute kidney injury
All patients (n = 1252) | AKI (n = 285) | No AKI (n = 967) | |
|---|---|---|---|
Age, year a | 58.0 (49.0–67.8) | 65.0 (54.0–71.0) | 57.0 (48.0–66.0) |
Male sexa | 685 (54.7%) | 176 (61.8%) | 509 (52.6%) |
Hypertension a | 321 (25.6%) | 112 (39.3%) | 209 (21.6%) |
Diabetes a | 286 (22.8%) | 108 (37.9%) | 178 (18.4%) |
Alcohol > 40 g/day | 244 (19.5%) | 65 (22.8%) | 179 (18.5%) |
Diagnosis at entry a | |||
CH | 1008 (80.5%) | 186 (18.5%) | 822 (81.5%) |
Com-LC | 123 (9.8%) | 34 (27.6%) | 89 (72.4%) |
Decom-LC or HCC | 121 (9.7%) | 65 (53.7%) | 56 (46.3%) |
Genotype | |||
1 | 545 (43.5%) | 108 (37.9%) | 437 (45.2%) |
2 | 603 (48.2%) | 150 (52.6%) | 453 (46.8%) |
3 | 101 (8.1%) | 26 (9.1%) | 75 (7.8%) |
Others | 3 (0.2%) | 1 (0.4%) | 2 (0.2%) |
Extrahepatic malignancy a | 90 (7.2%) | 35 (12.3%) | 55 (5.7%) |
SVR a | 606 (48.4%) | 49 (17.2%) | 557 (57.7%) |
HCV RNA > 600,000 IU/mL | 202 (16.1%) | 42 (14.7%) | 160 (16.5%) |
Albumin, g/dL a | 4.1 (3.7–4.4) | 3.7 (3.1–4.1) | 4.2 (3.9–4.5) |
Bilirubin, mg/dL a | 0.69 (0.50–1.00) | 0.77 (0.50–1.25) | 0.67 (0.50–0.94) |
Platelet, ×109/L a | 183.0 (131.0–232.0) | 151.0 (102.0–215.0) | 190.0 (142.0–233.0) |
PT-INR a | 1.03 (0.99–1.11) | 1.09 (1.02–1.22) | 1.01 (0.98–1.09) |
Child-Pugh B or C at entry a | 112 (8.9%) | 66 (58.9%) | 46 (41.1%) |
MELD score at entry a | 7.0 (6.0–8.0) | 8.0 (7.0–10.0) | 7.0 (6.0–8.0) |
Follow-up period (year) | 4.2 (2.1–7.9) | 4.6 (2.1–8.0) | 4.1 (2.0–7.8) |